Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

Drugmaker Merck , known as MSD outside of the U.S. and Canada, expects to increase its workforce across its India sites by ...

While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...

The federal crackdown on DEI initiatives is unlikely to deter companies from designing more representative trials, as it’s ...

(Reuters) -Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for ...

The majority of the market isn't seeing the bigger picture for these stocks and their underlying companies. Big mistake.

Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as ...

Mutations in BRCA1 do not appear to contribute significantly to the risk of prostate cancer progression, according to DNA ...

We recently compiled a list of the Top 12 Stocks to Buy According to Bourgeon Capital. In this article, we are going to take ...

SAN DIEGO, CA / ACCESS Newswire / February 20, 2025 / Robbins LLP reminds stockholders that a class action was filed on ...

Keytruda has been approved since 2016 as a second-line option after chemotherapy for patients with more advanced HNSCC that ...

Eikon Therapeutics is no stranger to eye-popping funding rounds, and the cancer-focused biotech has continued this trend with ...